In the study of Forde et al. (11), anti-PD-1 therapy increased the number of neoantigen-specific T cell clones in tumor and peripheral blood in resectable NSCLC, suggesting that TMB may be used as a predictor of treatment response. Here, PDCD1 is linked to neoplasm.